|Bid||1.7900 x 900|
|Ask||1.8700 x 800|
|Day's range||1.6800 - 1.8400|
|52-week range||1.5500 - 4.3000|
|Beta (5Y monthly)||-0.27|
|PE ratio (TTM)||N/A|
|Earnings date||10 May 2023 - 15 May 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.17|
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical